Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT07851662
Starting soon Not applicable

Functional Mobility and Resistance Exercise for Postmenopausal Females With Type 1 Diabetes

NCT07851662 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2026-12
Last updated
2026-10-01

Condition(s) studied

Type 1 Diabetes (T1D)Menopause

Investigational drug(s) / intervention(s)

Resistance exercise

Resistance exercise: Supervised progressive resistance exercise

Study summary

Improvements in diabetes care and technology have led to people with type 1 diabetes living longer. There are now more seniors than ever living with this complex health condition. With aging, type 1 diabetes affects both bone (more brittle), and muscle (loss of size and strength). This loss happens faster and to a greater extent in females than in males, and greatly increases the risk of frailty and falls. It may also occur more quickly in individuals who have higher blood glucose (sugar) levels.

Frailty is an important factor to address. In older females, even mild frailty decreases the ability to perform day-to-day tasks, and increases the risk of fractures, falls, hospitalization, and even death. Performing regular exercise helps to maintain the strength and quality of both muscles and bones with aging. The best type of exercise to help maintain the ability to perform activities of daily living (known as functional mobility) for this population is currently unknown. Resistance exercise (weightlifting) helps to prevent decreases in mobility in seniors without diabetes. However, in the context of type 1 diabetes, high blood sugar levels could negatively impact these potential strength benefits and low blood glucose could lead to falls. As such, any exercise program that causes swings in glucose levels may hinder rather than help.

The goal of this study is to evaluate the effect of weightlifting over a 6-month timeframe on functional mobility in postmenopausal females with type 1 diabetes, compared to a group that does not train. the investigators will also assess its effects on blood sugar variability and the risk of hypoglycemia. Like different medications, not all exercise is equal. Creating more knowledge about the benefits of specific types of exercise in this population will allow us to be more precise in our exercise recommendations for living longer and more independently with type 1 diabetes.

Eligibility

Sex
FEMALE
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * 1\) female * 2\) clinical diagnosis of T1D requiring continuous insulin therapy \[(either by multiple daily injections or continuous subcutaneous insulin infusion (insulin pumps)\] for \> 1 yr * 3\) aged ≥60 yrs, or ≥50 yrs with signs or symptoms of clinical frailty (level 4 on the Clinical Frailty Scale) * 4\) physically inactive (\<30 mins of aerobic activity \<3x/week; no resistance exercise) * 5\) postmenopausal (no menstrual periods in the previous 12 months, or who have had a hysterectomy and bilateral salpingo-oophorectomy with ≥1 yr having elapsed since surgery) Exclusion Criteria: * 1\) unable to communicate in English/French * 2\) unwilling/unable to sign informed consent * 3\) having performed RT in the past 6 months * 4\) recent (last 3 months) or multiple episodes (\>2 in last 12 months) of severe hypoglycemia and/or diabetic ketoacidosis * 5\) those with PA restrictions due to: * a) intermittent claudication * b) severe peripheral neuropathy * c) active proliferative retinopathy * d) unstable cardiac or pulmonary disease * e) disabling stroke * f) significant renal disease (estimated GFR\<25 mL/min/1.73 m2 or urine albumin/creatinine ratio \>150 mg/mmol) * g) uncontrolled hypertension (BP\>150 mmHg systolic or \>95 mmHg diastolic while seated) * h) musculoskeletal injury, foot wound or amputation that would affect the ability to exercise

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Alberta Diabetes Institute Edmonton Alberta
McMaster University Hamilton Ontario
Institut de recherches cliniques de Montreal Montreal Quebec

More Institut de Recherches Cliniques de Montreal trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07851662 on ClinicalTrials.gov ↗ ← All trials in Canada